The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile

Factors associated with weight gain in people treated with dolutegravir

(2020) Lucia Taramasso et al.   Open Forum Infectious Diseases

Inhibition of the mitochondrial complex-1 protects against carbon tetrachloride-induced acute liver injury

(2019) Hu Hua et al.   BIOMEDICINE & PHARMACOTHERAPY

Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease

(2019) Jin Lee et al.   ARCHIVES OF PHARMACAL RESEARCH

Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting

(2019) Kai Juhani Kauppinen et al.   AIDS PATIENT CARE AND STDS

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

96 weeks treatment of tenofovir alafenamide vs . tenofovir disoproxil fumarate for hepatitis B virus infection

(2018) Kosh Agarwal et al.   JOURNAL OF HEPATOLOGY

Brief Report

(2017) François Raffi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

(2016) Virginia A. Fonner et al.   AIDS

Impact of elvitegravir on human adipocytes: Alterations in differentiation, gene expression and release of adipokines and cytokines

(2016) Ricardo Moure et al.   ANTIVIRAL RESEARCH

Brief Report

(2016) David Wohl et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients

(2016) Roberta Gagliardini et al.   JOURNAL OF CHEMOTHERAPY

Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study

(2016) Helen Kovari et al.   Open Forum Infectious Diseases

Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy

(2015) Eisuke Murakami et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy

(2015) Anthony Mills et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial

(2015) Justin Mandala et al.   BMC Pharmacology & Toxicology

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

(2013) R. Campo et al.   CLINICAL INFECTIOUS DISEASES

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

(2010) Nina Friis-Møller et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION